SCYNEXIS Q1 2025 Earnings Report

SCYNEXIS EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.23
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SCYNEXIS Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.14 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SCYNEXIS Announcement Details

• Quarter: Q1 2025
• Date: 5/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

SCYNEXIS (NASDAQ:SCYX), a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.